1244760-90-4Relevant articles and documents
Pyridine carboxamides: Potent palm site inhibitors of HCV NS5B polymerase
Cheng, Cliff C.,Huang, Xiaohua,Shipps, Gerald W.,Wang, Yu-Sen,Wyss, Daniel F.,Soucy, Kyle A.,Jiang, Chuan-Kui,Agrawal, Sony,Ferrari, Eric,He, Zhiqing,Huang
scheme or table, p. 466 - 471 (2011/02/24)
Pyridine carboxamide-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase were diversified and optimized to a variety of topologically related scaffolds. In particular, the 2-methyl nicotinic acid scaffold was developed into inhibitors with improved biochemical (IC50-GT1b = 0.014 μM) and cell-based HCV replicon potency (EC50-GT1b = 0.7 μM). Biophysical and biochemical characterization identified this novel series of compounds as palm site binders to HCV polymerase.